The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

April 12, 2017

Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses toxicities associated with immunotherapy agents for the treatment of patients with osteosarcoma.

April 10, 2017

According to findings from a single-arm phase II trial, treatment with the PD-1 inhibitor nivolumab (Opdivo) resulted in an overall response rate of 24.3% in previously treated patients with squamous cell carcinoma of the anal canal.

April 07, 2017

Axitinib was a promising newcomer in the renal cell carcinoma field when it was introduced as a second-line therapy 5 years ago. Now it is being displaced by newer therapies, a development that may serve as a harbinger for the evolution of treatment patterns in other tumor types with a bounty of novel agents.

April 07, 2017

John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the CheckMate-026 trial in lung cancer.

April 07, 2017

Padmanee Sharma, MD, PhD, discusses the significance of the VISTA immune-checkpoint pathway in prostate cancer, and her proposed novel immunotherapy approach for patients with these tumors.

March 30, 2017

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges with treatment options for patients with T-cell lymphoma.

March 30, 2017

Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the differences in response to the same therapy for patients with follicular lymphoma.

March 28, 2017

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses trials investigating combinations of immunotherapy regimens in lung cancer.

March 22, 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses standard and emerging advances in the treatment of patients with HER2-positive breast cancer.

March 21, 2017

Hagop Kantarjian, MD, discusses the success of blinatumomab and next steps with the anti-CD19 agent.

March 18, 2017

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with anaplastic thyroid cancer.

March 15, 2017

Nancy B. Gordon, MD, assistant professor, Department of Pediatrics, The University of Texas MD Anderson Center, discusses next steps for immunotherapy research in the field of osteosarcoma.

March 13, 2017

John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging data with radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.

March 10, 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses why researchers and physicians should reconsider the utility of PD-L1 as a biomarker for patients with bladder cancer.

March 10, 2017

Brian F. Chapin, MD, discusses the importance of active surveillance in patients with prostate cancer at a low risk of developing metastases and the benefits of surgery and radiation as active treatment methods for patients with locally advanced disease.

March 10, 2017

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the agents available to treat patients with metastatic castration-resistant prostate cancer (mCRPC)

March 10, 2017

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the considering factors for a patient with prostate cancer to undergo active surveillance versus active treatment.

March 09, 2017

John C. Araujo, MD, PhD, discusses targeted therapies, current and emerging, for patients with bone-metastatic castration-resistant prostate cancer.

March 09, 2017

Eric Jonasch, MD, speaks on the evolving choices for patients with renal cell carcinoma in the first- and second-line settings, as well as the remaining challenges in the field.

March 08, 2017

John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of bone-targeting agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.